Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes

Neuroscience Letters

Volumn 451, Issue 3, 2009, Pages 185-189

  Lim, Ju Hee ^a   Kim, Sa Suk ^a   Boo, Doo Hyun ^a   No, Haja ^a   Kang, Bok Yun ^a   Kim, Eun Mee ^b   Hwang, Onyou ^b   Choi, Hyun Jin ^a  

^a Chonnam National University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Antioxidant enzyme; Bromocriptine; Cath.a; Nrf2; Parkinson's disease; Tetrahydrobiopterin (BH4)

Indexed keywords

BROMOCRIPTINE; CYTOCHROME C; ENZYME; LACTATE DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TETRAHYDROBIOPTERIN; TRANSCRIPTION FACTOR NRF2;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; ENZYME ACTIVITY; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; ANTIOXIDANTS; BIOPTERIN; BROMOCRIPTINE; CELL DEATH; CELL LINE; CYTOCHROMES C; DOPAMINE; DOPAMINE AGONISTS; ENZYMES; L-LACTATE DEHYDROGENASE; MICE; NEURONS; NEUROPROTECTIVE AGENTS; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PARKINSON DISEASE; RECEPTORS, DOPAMINE; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 59149106021     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.12.056     Document Type: Article

References (34)

1. Avila-Costa M., Colín-Barenque L., Montiel-Flores E., Aley-Medina P., Valdez A., Librado J., Martínez E., Martínez V., Mussali-Galante P., and Fortoul T. Bromocriptine treatment in a murine Parkinson's model: ultrastructural evaluation after dopaminergic deafferentation. Int. J. Neurosci. 115 (2005) 851-859
2. Chae S., Bang Y., Kim K., Lee K., Kang B., Kim E., Inoue H., Hwang O., and Choi H. Role of cyclooxygenase-2 in tetrahydrobiopterin-induced dopamine oxidation. Biochem. Biophys. Res. Commun. 359 (2007) 735-741
3. Choi H., Jang Y., Kim H., and Hwang O. Tetrahydrobiopterin is released from and causes preferential death of catecholaminergic cells by oxidative stress. Mol. Pharmacol. 58 (2000) 633-640
4. Choi H., Kim S., Lee S., and Hwang O. Dopamine-dependent cytotoxicity of tetrahydrobiopterin: a possible mechanism for selective neurodegeneration in Parkinson's disease. J. Neurochem. 86 (2003) 143-152
5. Choi H., Kim S., Lee S., Moon Y., and Hwang O. Involvement of apoptosis and calcium mobilization in tetrahydrobiopterin-induced dopaminergic cell death. Exp. Neurol. 181 (2003) 281-290
6. Choi H., Lee S., Cho Y., and Hwang O. Inhibition of vesicular monoamine transporter enhances vulnerability of dopaminergic cells: relevance to Parkinson's disease. Neurochem. Int. 46 (2005) 329-335
7. Choi H., Lee S., Cho Y., No H., Kim S., and Hwang O. Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson's disease. Neurochem. Int. 48 (2006) 255-262
8. Datta S., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., and Greenberg M. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
9. Gille G., Hung S., Reichmann H., and Rausch W. Oxidative stress to dopaminergic neurons as models of Parkinson's disease. Ann. N. Y. Acad. Sci. 1018 (2004) 533-540
10. Grewal S., York R., and Stork P. Extracellular-signal-regulated kinase signalling in neurons. Curr. Opin. Neurobiol. 9 (1999) 544-553
11. Hara H., Ohta M., and Adachi T. Apomorphine protects against 6-hydroxydopamine-induced neuronal cell death through activation of the Nrf2-ARE pathway. J. Neurosci. Res. 84 (2006) 860-866
12. Hwang Y., Kim H., Han E., and Jeong H. Metallothionein-III protects against 6-hydroxydopamine-induced oxidative stress by increasing expression of heme oxygenase-1 in a PI3K and ERK/Nrf2-dependent manner. Toxicol. Appl. Pharmacol. 231 (2008) 318-327
13. Itoh K., Ishii T., Wakabayashi N., and Yamamoto M. Regulatory mechanisms of cellular response to oxidative stress. Free Radic. Res. 31 (1999) 319-324
14. Jakel R., Townsend J., Kraft A., and Johnson J. Nrf2-mediated protection against 6-hydroxydopamine. Brain Res. 1144 (2007) 192-201
15. Kapitulnik J. Bilirubin: an endogenous product of heme degradation with both cytotoxic and cytoprotective properties. Mol. Pharmacol. 66 (2004) 773-779
16. Kaufman S. New tetrahydrobiopterin-dependent systems. Annu. Rev. Nutr. 13 (1993) 261-286
17. Kim S., Yang J., Kim M., Roh S., Kim H., Lee K., Jeong H., and Kang K. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic. Biol. Med. 45 (2008) 537-546
18. Lee S., Moon Y., Hee Choi D., Jin Choi H., and Hwang O. Particular vulnerability of rat mesencephalic dopaminergic neurons to tetrahydrobiopterin: relevance to Parkinson's disease. Neurobiol. Dis. 25 (2007) 112-120
19. Lee Y., Park S., Shin D., Hwang J., Park B., Park Y., Lee T., Chae H., Jin B., Oh T., and Oh Y. Oxidative modification of peroxiredoxin is associated with drug-induced apoptotic signaling in experimental models of Parkinson disease. J. Biol. Chem. 283 (2008) 9986-9998
20. Li J., Calkins M., Johnson D., and Johnson J. Role of Nrf2-dependent ARE-driven antioxidant pathway in neuroprotection. Methods Mol. Biol. 399 (2007) 67-78
21. Lim J., Kim K., Kim S., Hwang O., and Choi H. Bromocriptine activates NQO1 via Nrf2-PI3K/Akt signaling: novel cytoprotective mechanism against oxidative damage. Pharmacol. Res. 57 (2008) 325-331
22. Menzies F., Cookson M., Taylor R., Turnbull D., Chrzanowska-Lightowlers Z., Dong L., Figlewicz D., and Shaw P. Mitochondrial dysfunction in a cell culture model of familial amyotrophic lateral sclerosis. Brain 125 (2002) 1522-1533
23. Mukherjee S., Gangopadhyay H., and Das D. Broccoli: a unique vegetable that protects mammalian hearts through the redox cycling of the thioredoxin superfamily. J. Agric. Food Chem. 56 (2008) 609-617
24. Muralikrishnan D., and Mohanakumar K. Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice. FASEB J. 12 (1998) 905-912
25. Nagy N., Malik G., Fisher A., and Das D. Targeted disruption of peroxiredoxin 6 gene renders the heart vulnerable to ischemia-reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 291 (2006) H2636-2640
26. Nishibayashi S., Asanuma M., Kohno M., Gómez-Vargas M., and Ogawa N. Scavenging effects of dopamine agonists on nitric oxide radicals. J. Neurochem. 67 (1996) 2208-2211
27. Radad K., Gille G., and Rausch W. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol. Rep. 57 (2005) 701-712
28. Satoh T., Okamoto S., Cui J., Watanabe Y., Furuta K., Suzuki M., Tohyama K., and Lipton S. Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophilic [correction of electrophilic] phase II inducers. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 768-773
29. Sawada H., Ibi M., Kihara T., Urushitani M., Akaike A., Kimura J., and Shimohama S. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress. Ann. Neurol. 44 (1998) 110-119
30. Takahashi T., Morita K., Akagi R., and Sassa S. Heme oxygenase-1: a novel therapeutic target in oxidative tissue injuries. Curr. Med. Chem. 11 (2004) 1545-1561
31. Takashima H., Tsujihata M., Kishikawa M., and Freed W. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors. Exp. Neurol. 159 (1999) 98-104
32. Tatton W., Chalmers-Redman R., Brown D., and Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann. Neurol. 53 Suppl. 3 (2003) S61-S70 (discussion S70-62)
33. Yoshikawa T., Minamiyama Y., Naito Y., and Kondo M. Antioxidant properties of bromocriptine, a dopamine agonist. J. Neurochem. 62 (1994) 1034-1038
34. Zarkovic K. 4-Hydroxynonenal and neurodegenerative diseases. Mol. Aspects Med. 24 (2003) 293-303